Kłodzko County Hospital, Poland.
Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poland.
Adv Clin Exp Med. 2021 Jan;30(1):23-27. doi: 10.17219/acem/128746.
A myocardial infarction is a specific clinical condition characterized by a relatively high acute mortality rate. Earlier reperfusion results in a smaller infarct size and a lower mortality rate.
To assess the in-hospital mortality in patients with ST-elevation myocardial infarction (STEMI) regarding patients' characteristics, and the mechanisms behind the deterioration in hemodynamic and clinical status, in order to assess the possibility of preventing this type of death.
A group of 106 patients aged 64.5 ±11.3 years was divided into 2 groups: patients who died while hospitalized (group I; n = 5) and patients who survived while hospitalized for STEMI (group II; n = 101). Primary coronary intervention was performed in all individuals, with direct stent implantation in all but 1 patient. In all patients the standard medication was started or continued, depending on the patient's status. The demographic and selected clinical and biochemical parameters were compared between the study groups.
The patients in group I were significantly older than the survivors (76.2 ±12.7 compared to 64.0 ±11.0 years; p < 0.05). The group with fatal myocardial infarction had a lower left ventricular ejection fraction (LVEF) (31.7 ±12.8% compared to 60.4 ±11.0%; p < 0.05) and a higher maximal serum troponin level (973.6 ±1121.8 ng/mL compared to 453.2 ±924.2 ng/mL; p < 0.05). Interestingly, among the patients who died, the pain-to-balloon time was significantly shorter than in the myocardial infarction survivors (84 ±48 min compared to 342 ±504 min; p < 0.05).
The development of the medical care system has made invasive procedures available, improving outcomes in patients with acute myocardial infarction. This form of treatment is likely optimized to such an extent that any changes in the time before intervention will not substantially improve mortality rates.
心肌梗死是一种具有较高急性死亡率的特定临床病症。早期再灌注可导致梗死面积更小,死亡率更低。
评估 ST 段抬高型心肌梗死(STEMI)患者的住院期间死亡率,以及导致血流动力学和临床状况恶化的机制,从而评估预防这种类型死亡的可能性。
将 106 名年龄为 64.5±11.3 岁的患者分为 2 组:住院期间死亡的患者(组 I;n=5)和住院期间存活的 STEMI 患者(组 II;n=101)。所有患者均进行了直接支架植入的直接经皮冠状动脉介入治疗(PCI)。所有患者均开始或继续使用标准药物,具体取决于患者的情况。比较两组患者的人口统计学和选定的临床及生化参数。
组 I 的患者明显比幸存者年龄更大(76.2±12.7 岁比 64.0±11.0 岁;p<0.05)。致命性心肌梗死组的左心室射血分数(LVEF)更低(31.7±12.8%比 60.4±11.0%;p<0.05),血清肌钙蛋白峰值水平更高(973.6±1121.8ng/ml 比 453.2±924.2ng/ml;p<0.05)。有趣的是,在死亡患者中,疼痛至球囊时间明显短于心肌梗死幸存者(84±48min 比 342±504min;p<0.05)。
医疗保健系统的发展使介入治疗成为可能,从而改善了急性心肌梗死患者的预后。这种治疗形式可能已经优化到了这样一种程度,即在干预前的任何时间变化都不会显著降低死亡率。